Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
https://doi.org/10.14341/2072-0351-3596
Abstract
Aims.
To study the dynamics of body weight, waist circumference, blood lipid and insulin demand in patients with type 2 diabetes mellitus (T2DM) during first year of combined treatment with metformin and insulin analogues, compared with insulin analogue monotherapy.
Materials and Methods.
We examined 78 patients with T2DM on newly initiated insulin therapy, including 54 females and 24 males. Median age was 56 [51.0; 64.0] years, median disease duration ? 9 [6.8;14.0] years. Participants were subdivided in two groups. First group was comprised of 48 subjects (33 females and 15 males), who received monotherapy with insulin analogues (glargine, de- temir, biphasic Aspart 30 and Humalog Mix 25 or rapid-acting lispro and aspart). Second group included 30 patients (18 females and12 males), who were treated with combined therapy (insulin analogues plus metformin). We measured HbA1c, plasma lipid composition, BMI, waist circumference and insulin demand initially and after one year of follow-up.
Results.
We showed that combined therapy vs. insulin monotherapy allows better glycemic compensation while reducing insulin demand and lowering risks for weight gain.
Conclusions.
Combined insulin analogue plus metformin treatment delivers better metabolic control in patients with T2DM and is as- sociated with lower risks for body weight gain and increase in insulin demand against monotherapy with insulin analogues.
To study the dynamics of body weight, waist circumference, blood lipid and insulin demand in patients with type 2 diabetes mellitus (T2DM) during first year of combined treatment with metformin and insulin analogues, compared with insulin analogue monotherapy.
Materials and Methods.
We examined 78 patients with T2DM on newly initiated insulin therapy, including 54 females and 24 males. Median age was 56 [51.0; 64.0] years, median disease duration ? 9 [6.8;14.0] years. Participants were subdivided in two groups. First group was comprised of 48 subjects (33 females and 15 males), who received monotherapy with insulin analogues (glargine, de- temir, biphasic Aspart 30 and Humalog Mix 25 or rapid-acting lispro and aspart). Second group included 30 patients (18 females and12 males), who were treated with combined therapy (insulin analogues plus metformin). We measured HbA1c, plasma lipid composition, BMI, waist circumference and insulin demand initially and after one year of follow-up.
Results.
We showed that combined therapy vs. insulin monotherapy allows better glycemic compensation while reducing insulin demand and lowering risks for weight gain.
Conclusions.
Combined insulin analogue plus metformin treatment delivers better metabolic control in patients with T2DM and is as- sociated with lower risks for body weight gain and increase in insulin demand against monotherapy with insulin analogues.
About the Authors
Tatiana Ivanovna Romantsova
I.M. Sechenov First Moscow State Medical University, Moscow
T Sh Dzhavakhishvili
I.M. Sechenov First Moscow State Medical University, Moscow
O V Roik
I.M. Sechenov First Moscow State Medical University, Moscow
References
1. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analyses of clinical studies. J Am Coll Nutr. 2003 Oct;22(5):331–339.
2. Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005 Sep;31(4 Pt 2):4S51–4S56.
3. Bagg W, Plank LD, Gamble G, Drury PL, Sharpe N, Braatvedt GD. The effects of intensive glycaemic control on body composition in patients with type 2 diabetes. Diabetes Obes Metab. 2001 Dec;3(6):410–416.
4. Larger E, Rufat P, Dubois-Laforgue D, Ledoux S. Insulin and weight gain: myth or reality? Diabetes Metab. 2001 Nov;27(5 Pt 3):S23–27.
5. Yki-Yarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001 Apr;24(4):758–767.
6. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia. 1999 Apr;42(4):406–412.
7. Khan R. Weight gain and insulin therapy. Brit J Diabetes Vasc Dis. 2004;(4):264–267.
8. Russel-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes Metab. 2007 Nov;9(6):799–812.
9. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulfonylureas in type 2 diabetes. Diabet Med. 2006 Feb;23(2):128–133.
10. Golay A. Metformin and body weight. Int J Obes (Lond). 2008 Jan;32(1):61–72.
11. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type 11 noninsulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53.
12. Siram AT, Yanagisawa R, Skamagas M. Weight management in Type 2 Diabetes Mellitus. Mt Sinai J Med. 2010 Sep– Oct;77(5):533–548. doi: 10.1002/msj.20208.
13. Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism. 2011 Mar;60(3):327–334. doi: 10.1016/j.metabol.2010.02.007.
14. Eriksson A, Attvall S, Bonnier M, Eriksson JW, Rosander B, Karlsson FA. Short-term effects of metformin in type 2 diabetes. Diabetes Obes Metab. 2007 Jul;9(4):483–489.
15. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995 Aug 31;333(9):550–554.
16. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006 Aug;29(8):1963–1972.
Review
For citations:
Romantsova T.I., Dzhavakhishvili T.Sh., Roik O.V. Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment. Diabetes mellitus. 2013;16(1):48-51. (In Russ.) https://doi.org/10.14341/2072-0351-3596
Views:
1111
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
